

# Effect of Partially Hydrolyzed, Whey-based Infant Formulas on Growth and Tolerability in Healthy Term Infants

NCT05868408

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Société des Produits Nestlé (SPN)
Enrollment	234 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Written informed consent has been obtained from at least one parent (or other legally acceptable representative \[LAR\]), if applicable)
- Infant gestational age e37 completed weeks
- Infant birth weight of e2.5 kg and d4.5 kg
- Singleton birth
- Infant postnatal age d28 days (date of birth = day 0)
- ... and 2 more (see full listing online)

### Exclusion (7)

- Chronic infectious, metabolic, genetic illness or other disease, including any condition that impacts feeding or growth
- Major congenital or chromosomal abnormality known to affect growth (e.g., congenital heart disease, cystic fibrosis)
- Maternal medical conditions known to affect infant growth (e.g., untreated preeclampsia or gestational diabetes)
- Infants with special dietary needs other than standard infant formula
- Infants with known (or symptoms suggestive of) cow's milk protein intolerance/allergy, or lactose intolerance or severe food allergies that impact diet
- ... and 2 more (see full listing online)

## Locations (3 total)

---

National Guard Hospital, Jeddah, Saudi Arabia  
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia  
National Guard Hospital, Riyadh, Saudi Arabia

---

<https://clinicaltrials.gov/study/NCT05868408>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).